Quick Answer
A July 2026 Lancet trial found semaglutide (Ozempic) reduces liver scarring in advanced fatty liver disease including early cirrhosis — a first-ever finding with major implications for India's 300 million MASH patients.
Free Consultation
Have questions about GLP-1 Therapy?
Enter your phone number — a specialist calls you back in 30 minutes. Free, no commitment.
🔒 Confidential · No spam · 10,000+ patients helped
A major new clinical trial published on 15 July 2026 in The Lancet Gastroenterology and Hepatology has found that semaglutide — the active ingredient in Ozempic and Wegovy — can reduce liver scarring in patients with advanced fatty liver disease, including those who have already developed early-stage cirrhosis. This is the first time any drug has demonstrated this benefit in patients at this advanced stage, and for India — where an estimated 300 million people live with some form of fatty liver disease — the implications could not be more significant.
What the Study Found
Researchers at the University of California San Diego School of Medicine led a large international clinical trial evaluating semaglutide in patients with metabolic dysfunction-associated steatohepatitis — a condition known as MASH, which is the progressive, inflammatory form of fatty liver disease. Crucially, the study included patients not only with moderate liver fibrosis (scarring) but also those with compensated cirrhosis — meaning their livers were already significantly scarred but had not yet failed.
The results showed that semaglutide meaningfully reduced liver inflammation and fibrosis in both groups. For doctors and patients, this matters enormously. Liver fibrosis was previously considered largely irreversible once it reached the advanced stage. The finding that semaglutide can improve it — even in patients with early cirrhosis — upends a long-held assumption and opens a new treatment path for patients who previously had very few options outside of liver transplant.
The study results were published in the 15 July 2026 online edition of The Lancet Gastroenterology and Hepatology, one of the world's most authoritative medical journals.
Why This Matters So Much for India
Free Consultation
Have questions about GLP-1 Therapy?
Enter your phone number — a specialist calls you back in 30 minutes. Free, no commitment.
🔒 Confidential · No spam · 10,000+ patients helped
India carries one of the heaviest burdens of fatty liver disease in the world. Estimates suggest that between two-thirds and three-quarters of people with type 2 diabetes and obesity in India have some form of fatty liver disease. With India home to 77 million people with diagnosed diabetes — and many more undiagnosed — the number of Indians at risk for MASH and its complications runs into the hundreds of millions.
Fatty liver disease progresses silently. Most people with early fatty liver have no symptoms and discover the problem only on a routine ultrasound. Without treatment, it can advance over years and decades through stages of inflammation and fibrosis until cirrhosis sets in. At that point, the liver struggles to perform its essential functions — filtering toxins, producing clotting factors, regulating metabolism — and patients become vulnerable to liver failure, dangerous complications like internal bleeding, and liver cancer.
Until now, there was no approved drug to reverse fibrosis in advanced MASH. The standard advice was to lose weight, control blood sugar, and cut alcohol — all sound recommendations, but extremely difficult to sustain long-term for most patients. The new Lancet trial suggests that semaglutide may offer something patients did not previously have: a medical treatment that can actively repair liver damage, not just prevent further harm.
Wegovy Approved for MASH in India
The timing of this research aligns with recent developments in India's own regulatory landscape. India's Central Drugs Standard Control Organisation has already approved Novo Nordisk's Wegovy — semaglutide 2.4 mg — for the treatment of MASH in adults with moderate to advanced liver fibrosis. This makes semaglutide the first and, to date, only GLP-1 receptor agonist approved in India specifically for fatty liver disease treatment, not just weight loss or diabetes.
The new Lancet trial strengthens the evidence base for this approval considerably, particularly by extending the findings to patients with early cirrhosis — a population that was previously excluded from most clinical trials out of caution.
Free Consultation
Have questions about GLP-1 Therapy?
Enter your phone number — a specialist calls you back in 30 minutes. Free, no commitment.
🔒 Confidential · No spam · 10,000+ patients helped
What Indian Patients Should Know
If you have been told you have fatty liver, a high liver enzyme level, or liver fibrosis on an ultrasound or fibroscan, this research is directly relevant to you. The most important first step is finding out how advanced your liver disease is. A fibroscan — a quick, painless ultrasound-based test available at most large hospitals and diagnostic centres across India — can grade your liver stiffness and give a reliable estimate of your fibrosis stage without a liver biopsy.
If your fibroscan result shows significant fibrosis (F2, F3, or F4 / compensated cirrhosis) and you also have obesity or type 2 diabetes, you are likely to be a candidate for semaglutide treatment under the new approved indication. Your treating doctor — typically a gastroenterologist, hepatologist, or endocrinologist — should assess your complete metabolic and liver health profile and discuss whether a GLP-1 drug is appropriate for your situation.
The cost of Wegovy for MASH treatment in India is currently in the range of Rs 12,000 to Rs 18,000 per month for the 2.4 mg dose, though generic semaglutide options at lower doses are available at significantly lower prices. It is worth discussing with your specialist whether a lower dose would be appropriate as a starting point, and what the realistic trajectory for your liver health might look like over 6 to 12 months of treatment.
The big picture is genuinely optimistic. A drug already available in India, already approved for fatty liver disease, has now been shown in a Lancet-published trial to reverse scarring even in early cirrhosis. For millions of Indian patients who were previously told to simply watch and wait, this is a meaningful development worth discussing urgently with your doctor.
Call MySurgery at 8588967050 or WhatsApp us to speak with a GLP-1 specialist. Free consultation, callback in 30 minutes.
Free Consultation
Have questions about GLP-1 Therapy?
Enter your phone number — a specialist calls you back in 30 minutes. Free, no commitment.
🔒 Confidential · No spam · 10,000+ patients helped
Disclaimer: This article is based on information published on the referenced websites below and is intended for general awareness only. It is not a substitute for professional medical advice.
References: 1. UC San Diego Health — GLP-1 Shows Promise for Patients with Advanced Fatty Liver Disease — https://health.ucsd.edu/news/press-releases/2026-07-16-glp-1-shows-promise-for-patients-with-advanced-fatty-liver-disease/ 2. Medical Dialogues India — GLP-1 shows promise for patients with advanced fatty liver disease, suggests study — https://medicaldialogues.in/gastroenterology/news/glp-1-shows-promise-for-patients-with-advanced-fatty-liver-disease-suggests-study-175227 3. The Bridge Chronicle — India Approves Novo Nordisk's Wegovy for Fatty Liver Disease — https://www.thebridgechronicle.com/amp/story/news/nation/india-approves-wegovy-fatty-liver-disease
MySurgery GLP-1 Team
GLP-1 Research & Patient Education
Have questions about GLP-1 Therapy?
Free consultation. Expert doctors. Callback in 30 minutes.